XyloCor

Focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy

XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Lead product candidate XC001 is in clinical development for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, for patients with cardiac tissue damage from heart attacks.

VISIT SITE